IRIS
CRISCITIELLO, Carmen
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 751
NA - Nord America 334
EU - Europa 195
SA - Sud America 154
AF - Africa 37
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.472
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 271
SG - Singapore 237
CN - Cina 184
BR - Brasile 107
VN - Vietnam 103
IN - India 47
IT - Italia 44
FR - Francia 34
BD - Bangladesh 32
HK - Hong Kong 24
GB - Regno Unito 21
MX - Messico 21
AR - Argentina 20
CA - Canada 20
IQ - Iraq 19
SA - Arabia Saudita 16
TR - Turchia 16
DE - Germania 15
ES - Italia 11
PL - Polonia 11
ID - Indonesia 10
PK - Pakistan 10
DZ - Algeria 9
RU - Federazione Russa 9
PH - Filippine 8
EC - Ecuador 7
IE - Irlanda 7
MY - Malesia 7
UA - Ucraina 7
ZA - Sudafrica 7
CL - Cile 6
MA - Marocco 6
PT - Portogallo 6
CO - Colombia 5
EG - Egitto 5
FI - Finlandia 5
TH - Thailandia 5
DO - Repubblica Dominicana 4
TW - Taiwan 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
BE - Belgio 3
CZ - Repubblica Ceca 3
GT - Guatemala 3
JM - Giamaica 3
JO - Giordania 3
JP - Giappone 3
NL - Olanda 3
PE - Perù 3
SE - Svezia 3
SN - Senegal 3
SV - El Salvador 3
UZ - Uzbekistan 3
AT - Austria 2
BB - Barbados 2
ET - Etiopia 2
GR - Grecia 2
IL - Israele 2
KW - Kuwait 2
NP - Nepal 2
PA - Panama 2
PR - Porto Rico 2
RO - Romania 2
AL - Albania 1
BG - Bulgaria 1
BT - Bhutan 1
CD - Congo 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
HU - Ungheria 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LV - Lettonia 1
MN - Mongolia 1
MQ - Martinica 1
MW - Malawi 1
MZ - Mozambico 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
OM - Oman 1
PS - Palestinian Territory 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 1.472
Salva come PNG Salva come JPEG
Città #
Singapore 70
Beijing 52
Santa Clara 43
Ho Chi Minh City 32
Ashburn 25
San Jose 23
Hong Kong 22
Los Angeles 21
Hanoi 19
Buffalo 15
New York 13
Dallas 11
Assago 10
Orem 10
São Paulo 10
Da Nang 8
Mexico City 8
Frankfurt am Main 7
Hillsboro 7
Rio de Janeiro 6
Riyadh 6
Baghdad 5
Istanbul 5
Jeddah 5
London 5
Madrid 5
Maynooth 5
Montreal 5
New Delhi 5
Paris 5
The Dalles 5
Warsaw 5
Belo Horizonte 4
Chennai 4
Dammam 4
Dhaka 4
Durban 4
Helsinki 4
Kuala Lumpur 4
Phú Thọ 4
Quito 4
Santiago 4
Toronto 4
Baku 3
Bangkok 3
Barnet 3
Batna City 3
Bexley 3
Boardman 3
Bogotá 3
Cairo 3
Casablanca 3
Council Bluffs 3
Dakar 3
Houston 3
Hyderabad 3
Lahore 3
Mumbai 3
Padua 3
Rome 3
Surat 3
Tashkent 3
Vancouver 3
Wroclaw 3
Addis Ababa 2
Amman 2
Amsterdam 2
Araguari 2
Araucária 2
Assis 2
Batam 2
Bridgetown 2
Can Tho 2
Chandigarh 2
Chicago 2
City of London 2
Concepción 2
Congonhas 2
Conselheiro Lafaiete 2
Dnipro 2
Dublin 2
Faisalabad 2
Florence 2
Fortaleza 2
Guatemala City 2
Guayaquil 2
Haiphong 2
Huế 2
Hải Dương 2
Jakarta 2
Jaraguá do Sul 2
José C. Paz 2
Kaohsiung 2
Karachi 2
Kingston 2
Kuwait City 2
Lima 2
Limburg an der Lahn 2
Lisbon 2
Lviv 2
Totale 652
Salva come PNG Salva come JPEG
Nome #
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) 48
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer 35
Nipple sparing mastectomy as a risk‐reducing procedure for brca‐mutated patients 35
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study 29
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer 24
PARP Inhibitors for Breast Cancer Treatment 22
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors 21
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer 19
Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey 19
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents 16
Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021 16
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations 16
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer 15
Impact of Rehabilitation on Breast Cancer Related Fatigue : A Pilot Study 15
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research 14
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 14
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00 13
Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists 13
Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine 13
Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow 13
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics 13
Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care 13
Variant allele frequency: a decision-making tool in precision oncology? 13
A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer 12
Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status 12
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer 12
Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials 12
Evolution of low HER2 expression between early and advanced-stage breast cancer 11
Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer 11
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study 11
Health-Related Quality of Life Among Patients With HR+/HER2- Early Breast Cancer 11
PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer 10
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer 10
Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy 10
The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario? 10
A multidisciplinary approach to an unusual medical case of locally advanced gastric cancer: a case report 10
[Exemestane in the treatment of breast carcinoma: recent findings] 10
Adjuvant treatment of early male breast cancer 10
Antibody–drug conjugates in solid tumors: a look into novel targets 10
Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars : a physician survey in the united states and emerging markets 10
RNAi screens identify CHD4 as an essential gene in breast cancer growth 10
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer 10
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials 10
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study 9
Expression of tumor-associated antigens in breast cancer subtypes 9
HER2-positive circulating tumor cells in breast cancer 9
Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence 9
Best management of locally advanced inoperable breast cancer 9
Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management 9
Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art 9
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 9
Neoadjuvant model for testing emerging targeted therapies in breast cancer 9
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus 9
Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial 9
Tumori maligni del colon 9
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience 9
The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy 9
Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation 9
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project 8
Targeting fibroblast growth factor receptor pathway in breast cancer 8
Immunotherapy of Breast Cancer 8
Mechanism of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist 8
How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed? 8
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials 8
Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer 8
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment 8
Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection 8
Editorial : Diagnosis and Treatment of Breast Cancer in 2022 : The Rise of Novel Molecular Biomarkers 8
Successes and limitations of targeted cancer therapy in breast cancer 8
QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review 8
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy 8
Understanding the biology of triple-negative breast cancer 8
Locoregional recurrence in patients with HER2 positive breast cancer 8
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer 8
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines 8
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution 8
Peptide vaccines in early breast cancer 8
Entinostat for the treatment of breast cancer 8
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing 8
Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials 8
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials 7
Cancer Immunotherapy and Identification of Prognostic and Predictive Biomarkers 7
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer : results from Neo-ALTTO 7
Tumor-associated antigens in breast cancer 7
Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting 7
Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial 7
Targeting the subtypes of breast cancer: Rethinking investigational drugs 7
Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours 7
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion 7
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management 7
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer 7
Think “HER2” different: integrative diagnostic approaches for HER2-low breast cancer 7
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy 7
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability 7
Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact 7
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread 7
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience 7
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management 7
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial 7
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies 7
Totale 1.112
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.459
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.459
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224 0 0 0 0 0 0 0 0 2 0 2 0
2022/20234 2 0 1 0 0 0 0 0 0 1 0 0
2023/20245 0 1 1 0 0 0 0 0 1 0 1 1
2024/202515 0 0 1 0 1 3 1 0 1 6 0 2
2025/20261.646 11 2 4 14 1 1 8 801 338 244 133 89
Totale 1.674